Day: July 16, 2021
Verkkokauppa.com Oyj Half-Year report 16 July 2021, 8:00 a.m. EEST
HALF-YEAR REPORT for 1 January – 30 June 2021
GROWTH CONTINUED WITH RECORD–HIGH SECOND QUARTER OPERATING PROFIT
Verkkokauppa.com arranges two news conferences today. News conference in Finnish is held at 10:00 am Finnish time. Another news conference for analysts and institutional investors is in English is at 11:00 am Finnish time. Details of the events can be found at the end of this release.
The complete report is attached to this release and also available at https://investors.verkkokauppa.com/en
Unless otherwise stated, the comparison figures in brackets refer to the corresponding period in the previous year (reference period). Figures are unaudited.
April – June 2021 in briefRevenue was 130.5 million euros (123.1)
Gross profit was 22.4 million...
Second quarter report 2021
Written by Customer Service on . Posted in Public Companies.
Please find the second quarter report for Sbanken Boligkreditt AS enclosed.
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading ActAttachmentSbanken Boligkreditt AS – Q2 2021 Report
Strong underlying performance in a unique quarter for Sbanken
Written by Customer Service on . Posted in Public Companies.
Bergen, 16 July 2021. The Sbanken group generated a profit before tax of NOK 253.2 million in the second quarter of 2021, compared with NOK 210.6 million in the second quarter of 2020. Net interest income increased by NOK 8.4 million, while net fee and commission income increased by NOK 4.1 million. Return on equity (ROE) in the second quarter was 11.1 per cent. Adjusting for excess CET1 capital above the 13.0 per cent target, ROE for the quarter equalled 14.9 pent.
At quarter-end, customer lending totalled NOK 82.0 billion, corresponding to an annual lending growth rate of minus 2.9 per cent. Mortgage churn was elevated in the month of May, while mortgage growth was moderately positive in June. Funds under management (FuM) increased to NOK 29.4 billion, a result of positive market sentiment and continued high inflow from customers.
Highlights:·...
VERKOKAUPPA.COM UPDATES ITS DISCLOSURE POLICY
Written by Customer Service on . Posted in Public Companies.
VERKOKAUPPA.COM UPDATES ITS DISCLOSURE POLICY
VERKKOKAUPPA.COM STOCK EXCHANGE RELEASE 16 JULY 2021 at 7.50 am EEST
Verkkokauppa.com’s Board of Directors has on 15 July 2021 approved the company’s updated disclosure policy, which describes the key principles Verkkokauppa.com observes in its investor communications with different capital market representatives and the media, as well as in its financial reporting.
The main changes to the disclosure policy concern changes in persons responsible for the company’s investor communications, as well as the length of the so-called silent period.
Each financial results publication is preceded by a silent period during which representatives of Verkkokauppa.com will not comment on the company’s financial position or future outlook, or meet with representatives of the financial community...
Verkkokauppa.com decided on the second installment of the quarterly dividend
Written by Customer Service on . Posted in Public Companies.
Verkkokauppa.com Oyj Stock Exchange Release 16 July 2021 at 7:45 am EEST
Verkkokauppa.com decided on the second installment of the quarterly dividend
The Board of Directors of Verkkokauppa.com Oyj has decided today, on the basis of the authorization granted by the Annual General Meeting 2021, that a dividend of EUR 0.058 per share (EUR 2,594,497.70 in total) be distributed from retained earnings.
The dividend will be paid to a shareholder registered in the company’s shareholders’ register maintained by Euroclear Finland Ltd on the record date for the dividend on 20 July 2021. The dividend will be paid on 27 July 2021.
Verkkokauppa.com’s Annual General Meeting, held on 25 March 2021, resolved to authorize the Board of Directors to decide at its discretion on the distribution of dividends. Based on the authorization, the total amount of...
Erasca Announces Pricing of Upsized Initial Public Offering
Written by Customer Service on . Posted in Public Companies.
SAN DIEGO, July 15, 2021 (GLOBE NEWSWIRE) — Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of its upsized initial public offering of 18,750,000 shares of common stock at an initial public offering price of $16.00 per share. All of the shares are being offered by Erasca. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Erasca, are expected to be $300.0 million. The shares are expected to begin trading on the Nasdaq Global Select Market on July 16, 2021 under the ticker symbol “ERAS.” The offering is expected to close on July 20, 2021, subject to the satisfaction of customary...
Report of Acquisition of Common Shares of Fancamp Exploration Ltd.
Written by Customer Service on . Posted in Public Companies.
VANCOUVER, British Columbia, July 15, 2021 (GLOBE NEWSWIRE) — Mr. Ashwath Mehra reports that ASTOR Management AG, a company that he controls, purchased today 22,000,000 common shares of Fancamp Exploration Ltd. (“Common Shares”) through the TSX Venture Exchange at $0.11 per share for total consideration paid of $2,420,000.
Immediately prior to the purchase of the Common Shares, Mr. Mehra had beneficial ownership and control of 2,750,000 Common Shares, representing 1.6% of the outstanding Common Shares. Mr. Mehra currently has beneficial ownership and control of 24,750,000 Common Shares, representing 14.0% of the outstanding Common Shares.
Mr. Mehra has acquired the Common Shares for investment and may acquire additional Common Shares or dispose of Common Shares (through market or private transactions) from time to time.
A copy...
P. Peter Pascali Updates Early Warning Report
Written by Customer Service on . Posted in Public Companies.
MONTREAL, July 15, 2021 (GLOBE NEWSWIRE) — P. Peter Pascali, President and Chief Executive Officer of PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX: PYR) (NASDAQ: PYR) (FRA: 8PY), a high-tech company (hereinafter referred to as the “Company” or “PyroGenesis”), that designs, develops, manufactures and commercializes plasma atomized metal powders, environmentally friendly plasma waste-to-energy systems and clean plasma torch products, has filed today an updated early warning report with respect to his shareholdings in PyroGenesis in connection with his proposed disposition (the “Proposed Disposition”) through the facilities of the Toronto Stock Exchange of up to 765,000 common shares of PyroGenesis (“Common Shares”) held by Fiducie de Crédit Mellon Trust (the “Trust”) under an automatic securities disposition plan (“ASDP”)...
AgJunction to Provide Automation Kits to Leading Equipment Manufacturer Komatsu Ltd.
Written by Customer Service on . Posted in Public Companies.
SCOTTSDALE, Ariz., July 15, 2021 (GLOBE NEWSWIRE) — AgJunction Inc. (TSX: AJX), (“AgJunction”), through its wholly-owned subsidiary Novariant, Inc. (“Novariant”), has been chosen by Komatsu Ltd. (“Komatsu”), an industry-leading manufacturer and supplier of equipment for the construction, mining equipment, utilities, forestry and industrial markets to provide sophisticated automation kits for construction workplaces.
The contract has been awarded following Novariant’s successful integration of customized autosteering systems for Komatsu’s equipment for agricultural use. Novariant currently provides automation modules that support mapping, path planning, and autosteering for Komatsu’s construction equipment platforms used in agricultural applications.
“After the successful integration of the customized autosteering,...
Mesoblast Presents Respiratory Function Results of COVID-19 ARDS Trial at Pulmonary Disease Conference
Written by Customer Service on . Posted in Public Companies.
NEW YORK, July 15, 2021 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today presented clinical outcomes from the randomized controlled trial of remestemcel-L in ventilator-dependent COVID-19 patients with moderate/severe acute respiratory distress syndrome (ARDS). Results of respiratory function were highlighted at the biennial Stem Cells, Cell Therapies, and Bioengineering in Lung Biology and Diseases conference hosted by the University of Vermont, Burlington, VT, on July 15. The invited presentation was given by Mesoblast Chief Executive Officer, Dr Silviu Itescu, and materials have been lodged with the ASX.
The trial in mechanically ventilated COVID-19 patients with moderate/severe ARDS enrolled 222 patients across the United States, of...